Spontaneous tumour lysis syndrome in multiple myeloma with loss of 17p13.1, t(4;14) and monosomy 13.
Bushra TbakhiSandrine HannaYazan SamhouriDeeraj LingutlaPublished in: BMJ case reports (2021)
Tumour lysis syndrome (TLS) is a constellation of metabolic derangements caused by lysis of tumour cells. It is an oncological emergency that is considered a rare occurrence in multiple myeloma (MM) and usually occurs after patients have been treated with chemotherapy. We describe a very rare case of TLS occurring before the official diagnosis or treatment of MM. We report infrequent karyotype abnormalities, including loss of 17p13.1 (TP53 mutation), t(4;14) (FGFR3/IGH fusion) and monosomy 13, that have not been explicitly described in association with spontaneous tumour lysis syndrome (STLS) in MM. This case adds to the sparse literature available on STLS in MM, which is a life-threatening situation requiring urgent medical intervention.
Keyphrases
- multiple myeloma
- rare case
- end stage renal disease
- healthcare
- case report
- newly diagnosed
- randomized controlled trial
- induced apoptosis
- systematic review
- ejection fraction
- chronic kidney disease
- public health
- risk assessment
- prostate cancer
- peritoneal dialysis
- oxidative stress
- radical prostatectomy
- cell cycle arrest
- patient reported outcomes
- radiation therapy
- cell death
- combination therapy
- robot assisted